Mylan Pays $9M To Settle Paclitaxel Patent Suit
Mylan, the largest maker of generic drugs in the U.S., said the payment will end a lawsuit pending in federal court in Pittsburgh. Under the settlement, Mylan will have a paid-up license to sell paclitaxel under Mayne's patents.
“The parties will promptly file stipulations of dismissal with prejudice with the U.S. District Court for the Western District...
Already a subscriber? Click here to login